Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.59 |
| ▸ | FAAH | O00519 | 2/20 | 0.57 |
| ▸ | CHRND | Q07001 | 5/20 | 0.53 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.53 |
| ▸ | CHRNG | P07510 | 1/20 | 0.53 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875301 | 1.00 | GRIA1 (0.59) | GRIA1FAAHCHRNDCHRNA1CHRNG | |
| SCHEMBL12148893 | 0.94 | GRIA1 (0.66) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL5817448 | 0.89 | FAAH (0.71) | GRIA1FAAHEPHX2 | |
| SCHEMBL12148897 | 0.85 | SLC6A5 (0.49) | GRIA1FAAHEPHX2LPAR3 | |
| SCHEMBL14102592 | 0.85 | EPHX2 (0.59) | GRIA1FAAHCHRNDEPHX2 | |
| SCHEMBL14102642 | 0.85 | EPHX2 (0.59) | GRIA1FAAHCHRNDEPHX2 | |
| SCHEMBL14102844 | 0.85 | EPHX2 (0.59) | GRIA1FAAHCHRNDEPHX2 | |
| SCHEMBL12148793 | 0.83 | GRIA1 (0.56) | GRIA1FAAHCHRNDCHRNA1CHRNG | |
| SCHEMBL13339067 | 0.82 | GRIA1 (0.56) | GRIA1FAAHCHRNDCHRNA1CHRNG | |
| SCHEMBL9519035 | 0.82 | CHRNB2 (0.69) | GRIA1FAAHCHRNDCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877729-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2014-11-04 | — | — | US | claimed |
| US-20140037714-A1 | AMINO ACID LIPIDS AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2014-02-06 | — | — | US | claimed |
| EP-3434259-A1 | AMINO ACID LIPIDS AND USES THEREOF | Marina Biotech, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180353607-A1 | LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2018-12-13 | — | — | US | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-8877729-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140037714-A1 | AMINO ACID LIPIDS AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8501824-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2494993-A2 | Amino acid lipids and uses thereof | Marina Biotech, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110177160-A1 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2157982-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, Inc. (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008137758-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | GRIA1 1430/4885FAAH 1738/4885CHRND 4783/4885 |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | GRIA1 1288/4885FAAH 1551/4885CHRND 4881/4885 |
| US-20140037714-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | GRIA1 1288/4885FAAH 1551/4885CHRND 4881/4885 |
| US-20180353607-A1 | LIPIDS FOR DELIVERY OF THERAPEUTICS | APOB, ABHD16A, LIPA | GRIA1 1286/4885FAAH 899/4885CHRND 4823/4885 |
| US-20110177160-A1 | Amino acid lipids and uses thereof | AADAT, AARS1, ABAT | GRIA1 1288/4885FAAH 1551/4885CHRND 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.